Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1240 studies found for:    Open Studies | "Lymphoma"
Show Display Options
Rank Status Study
21 Recruiting A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Condition: B-Cell Lymphoma
Intervention: Drug: CPI-1205
22 Recruiting DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
Condition: Lymphoma
Intervention: Other: laboratory biomarker analysis
23 Recruiting Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Rituximab
24 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Condition: Follicular Lymphoma
Interventions: Biological: PF-05280586;   Biological: MabThera®
25 Recruiting Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Rituximab, bendamustine
26 Recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
27 Not yet recruiting A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Condition: B-cell Lymphoma
Interventions: Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine
28 Recruiting Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
29 Not yet recruiting Phase II Study of TAK228 in Relapsed Lymphoma
Condition: Lymphoma
Interventions: Drug: TAK228;   Other: Blood Sugar Testing
30 Recruiting Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
31 Recruiting The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Condition: Non-Hodgkin Lymphoma
Intervention:
32 Recruiting Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
33 Recruiting Maintenance Lenalidomide in Lymphoma
Condition: Lymphoma
Intervention: Drug: Lenalidomide
34 Recruiting S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
35 Recruiting Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
Condition: B-cell Lymphomas
Intervention: Genetic: Anti-CD19 CAR T cells
36 Recruiting Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab (GA101)
37 Recruiting Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Lenalidomide
38 Recruiting Brazilian Network for Lymphoma Registry
Condition: Lymphoma
Intervention: Other: Observational, non-intervention
39 Recruiting Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: G-CSF
40 Not yet recruiting Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Venetoclax

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.